阿立哌唑联合氟伏沙明治疗难治性强迫症的临床对照研究

A comparison analysis on the efficacy of fluvoxamine combined with aripiprazole in the treatment of refractory obsessive- compulsive disorder

目的:观察阿立哌唑联合氟伏沙明治疗难治性强迫症的疗效。方法:将符合条件的60例难治性强迫症患者随机分成两组各30例,分别给予氟伏沙明联合阿立哌唑(试验组)和单独使用氟伏沙明(对照组),进行12周的系统治疗,使用Y-BOCS(Yale-Brown强迫量表)、HAMA(汉密尔顿焦虑量表)评估其疗效;以TESS(副反应量表)和有关的试验室检查评定副反应。结果:治疗以后两组患者的Y-BOCS评分均明显下降,试验组的治疗效果较好,两组之间差异存在显著性(P<0.01),并且试验组起效快;两组HAMA量表的评分明显下降,试验组的治疗效果较好,两组之间差异存在显著性(P<0.01),试验组起效快;试验组的副反应发生率高于对照组,但差异无显著性,两组药物引起的副反应均为轻度或中度,患者耐受性好。结论:氟伏沙明联合阿立哌唑对于治疗难治性强迫症具有良好的疗效,并且安全性高。

Objective： To compare the efficacy of fluvoxamine combined with aripiprazole in the treatment of refractory obsessive -compulsive disorder. Methods：60 patients with refractory obsessive -compulsive disorder were randomly assigned into two groups. One group was treated with fluvoxamine and aripiprazole and the other group with fluvoxamine alone for 12 weeks. The study was conducted in order to evaluate efficacy and side effects with the Y - BOCS, HAMA, the TESS and related lab tests. Re- suits ： The scores in the Y - BOCS, HAMA were descended, the group of combining fluvoxamine and aripiprazole was better than the other group in the efficacy, and there had significant statistical differences （P 〈 0.01 ）. The group of combining fluvoxamine and aripiprazole took effect more quickly. The side effect of using fluvoxamine and aripiprazole was higher than using fluvoxamine alone, but there were no statistical differences ; The side effects caused by the two groups are all low - grade or middle - grade. The endurance of suffers is better and the appearance of side effect varies. Conclusion ： The efficacy of group fluvoxamine and aripiprazole was better than the group of fluvoxamine alone, the group of combining fiuvoxamine and aripiprazole took effect more quick- ly and had much better effect than the other group in treatment of anxiety. The side effect of the two groups was slight and the appearance of side effect varies. The combination of fluvoxamine and aripiprazole are efficacy and safety in the treatment of refractory Obsessive - compulsive disorder.